New trial
Spotlight
Phase 2 trial: V940 mRNA cancer vaccine & Pembrolizumab PD-1 inhibitor in advanced melanoma
- Trial ID
- NCT06961006 on ClinicalTrials.gov
- Cancer type
- Melanoma
- Stage of research
- Exploratory
- Location
- 7 Locations
- Published in
- New in Oncology - July 25, 2025
This Phase 2 study evaluates whether a patient-specific TAA mRNA vaccine (V940) given by IM injection alongside IV pembrolizumab (a PD-1 inhibitor) can prolong progression-free survival compared to placebo plus pembrolizumab in patients with unresectable, advanced melanoma. Sponsored by Merck Sharp & Dohme LLC, the randomized, double-blind trial aims to advance translational insights in immuno-oncology.
More in melanoma
-
New trial · Oct 22, 2026 · NCT07869381
Randomized trial compares comprehensive margin assessment with standard pathology after melanoma surgery -
New trial · Oct 15, 2026 · NCT07830225
Phase 2 pilot uses ctDNA to guide checkpoint-inhibitor discontinuation in advanced melanoma with disease control -
Trial result · Oct 8, 2026 · NCT06566092
Lifileucel produces confirmed responses in 2 of 3 treated adolescents with ICI-refractory metastatic melanoma -
New trial · Oct 8, 2026 · NCT07804186
Phase 3 darovasertib PKC inhibitor plus crizotinib c-MET/ALK inhibitor in adjuvant uveal melanoma -
New trial · Oct 8, 2026 · NCT07815574
Phase 3 iSCIB1+ gp100/TRP-2 DNA vaccine adds melanoma antigen targeting to PD-1/CTLA-4 blockade.